GlassScriptPhysician profile
Michael J Zumer
NPI 1144492786
$27,802.60
in general payments reported to CMS, 2019-2025
32 companies · $5,444 in 2025
The $5,444 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $6,207 · 2022: $7,288 · 2023: $4,379 · 2024: $4,484 · 2025: $5,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $247 · Consulting Fee: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,960.12 |
| Education | $247.14 |
| Consulting Fee | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,029.10 | 2021-2025 | |
| Amgen INC. | $6,588.40 | 2021-2025 | Tavneos, Enbrel, Otezla |
| Pfizer INC. | $2,965.80 | 2021-2025 | |
| Janssen Biotech, INC. | $2,579.39 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Ucb, INC. | $1,217.89 | 2021-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $1,153.89 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $1,108.81 | 2021-2025 | |
| Glaxosmithkline, LLC. | $946.56 | 2021-2025 | Benlysta, Shingrix, Arexvy |
| Lilly USA, LLC | $812.69 | 2021-2025 | Taltz |
| Genzyme Corporation | $661.51 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $441.65 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $414.83 | 2021-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $247.66 | 2024-2025 | Orencia |
| Organon LLC | $239.69 | 2023-2025 | Hadlima, Renflexis |
| Sobi, INC | $232.37 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $208.81 | 2021 | |
| Aurinia Pharma U.S., INC. | $152.21 | 2021-2024 | Lupkynis |
| Radius Health, INC. | $124.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.85 | 2021-2025 | Ofev |
| Kyowa Kirin, INC. | $104.97 | 2024-2025 | Crysvita |
| Cardinal Health 110 LLC | $100.00 | 2025 | |
| Fresenius Kabi USA, LLC | $73.06 | 2023-2025 | Idacio |
| Kiniksa Pharmaceuticals International, Plc | $66.64 | 2024 | Arcalyst |
| Ultragenyx Pharmaceutical INC. | $55.85 | 2021 | |
| Novo Nordisk INC | $36.78 | 2022-2023 | Wegovy |
| Pacira Therapeutics, INC. | $25.68 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $22.36 | 2025 | Zilretta |
| Invivyd INC | $21.79 | 2025 | Pemgarda |
| Swing Therapeutics, INC. | $18.64 | 2025 | Stanza |
| Antares Pharma, INC. | $16.55 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Alexion Pharmaceuticals, INC. | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zumer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.